Lu AG06474
Alternative Names: Lu-AG-06474Latest Information Update: 17 Jul 2024
At a glance
- Originator Lundbeck A/S
- Class Small molecules
- Mechanism of Action Monoacylglycerol lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
- Preclinical Neurological disorders; Psychiatric disorders
Most Recent Events
- 17 May 2024 Lundbeck completes Phase-I clinical trials in Unspecified (In volunteers) in Netherlands (PO) (NCT06077786)
- 01 Dec 2023 Preclinical trials in Neurological disorders in Denmark (unspecified route) prior to December 2023 (Lundbeck AS pipeline, December 2023)
- 01 Dec 2023 Preclinical trials in Psychiatric disorders in Denmark (unspecified route) prior to December 2023 (Lundbeck AS pipeline, December 2023)